Selling, General, and Administrative Costs: Zoetis Inc. vs MorphoSys AG

Zoetis vs MorphoSys: A Decade of SG&A Insights

__timestampMorphoSys AGZoetis Inc.
Wednesday, January 1, 201496890001643000000
Thursday, January 1, 2015104310001532000000
Friday, January 1, 201696180001364000000
Sunday, January 1, 2017123480001334000000
Monday, January 1, 2018283102411484000000
Tuesday, January 1, 2019593361471638000000
Wednesday, January 1, 20201591459411726000000
Friday, January 1, 20211998000002001000000
Saturday, January 1, 2022902250002009000000
Sunday, January 1, 2023925380002151000000
Monday, January 1, 20242318000000
Loading chart...

Unleashing insights

A Comparative Analysis of SG&A Expenses: Zoetis Inc. vs MorphoSys AG

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Zoetis Inc. and MorphoSys AG from 2014 to 2023. Over this period, Zoetis Inc. consistently outpaced MorphoSys AG in SG&A spending, reflecting its expansive operational scale. In 2023, Zoetis Inc.'s SG&A expenses reached approximately $2.15 billion, marking a 31% increase from 2014. In contrast, MorphoSys AG's expenses peaked in 2021 at nearly $200 million, a significant rise from its 2014 figures. This disparity highlights Zoetis Inc.'s robust market presence and strategic investments in growth, while MorphoSys AG's more modest spending underscores its focused approach. As the industry continues to grow, these financial strategies will play a pivotal role in shaping the future trajectories of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025